3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
54
Lymphoma
44
Lymphoma, Large B-Cell, Diffuse
35
Lymphoma, Follicular
31
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Lymphoma, Non-Hodgkin
22
Multiple Myeloma
19
Leukemia
17
Burkitt Lymphoma
13
Hodgkin Disease
12
Lymphoma, Mantle-Cell
10
Neoplasms
9
Lymphoma, Large-Cell, Immunoblastic
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, Large-Cell, Anaplastic
7
Neoplasms, Plasma Cell
6
Neoplasm Metastasis
6
Lymphoma, T-Cell, Peripheral
6
Recurrence
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pain
3
Lymphoma, B-Cell
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Myasthenia Gravis
2
Leukemia, Biphenotypic, Acute
2
Disease
2
Interventions
pirtobrutinib
5
Lenalidomide
4
Rituximab
3
Imatinib Mesylate
3
ruxolitinib
2
ponatinib
2
ibrutinib
2
Platelet Transfusion
2
Brentuximab Vedotin
2
Bortezomib
2
Bendamustine Hydrochloride
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
zanubrutinib
1
vosaroxin
1
venetoclax
1
nilotinib
1
idelalisib
1
bosutinib
1
acalabrutinib
1
Zoledronic Acid
1
Vorinostat
1
Vincristine
1
Tretinoin
1
Prednisone
1
Plasma Exchange
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Exercise
1
Doxorubicin
1
Dexamethasone
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Diseases
×
Prednisone
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA